MORRISVILLE, N.C.--(BUSINESS WIRE)--Aug. 9, 2006--BioDelivery Sciences International, Inc. (NASDAQ:BDSI - News) is using its patented Bioral® (Nanocochleate(TM)) delivery technology to deliver a siRNA therapeutic in a mouse model of influenza. The siRNA being used targets critical gene segments shared by avian influenza (H5N1). BDSI’s licensed and patented Bioral® drug delivery technology encapsulates and protects the selected therapeutic in a nanocrystalline structure termed a “cochleate”. All of the components of the cochleate are naturally-occurring substances.
